Our previous study found that OCA can alleviate NAFLD by reducing hepatic fatty acid uptake through the inhibition of fatty acid transporter protein 5, and this pathway is independent of FXR (Lin et al., 2022b). Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.